Consolidated Statements of Comprehensive Loss (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Revenues:
Clinical treatment programs	$ 39	$ 45	$ 160	$ 123
Total Revenues	39	45	160	123
Costs and Expenses:
Production/cost of goods sold	988	217	1,476	614
Research and development	2,357	1,750	5,758	5,014
General and administrative	1,659	1,635	5,271	4,890
Total costs and expenses	5,004	3,602	12,505	10,518
Operating loss	(4,965)	(3,557)	(12,345)	(10,395)
Interest expense	(7)	(9)	(19)	(21)
Interest and other income	353	212	873	686
Funds received from sale of income tax net operating losses			1,328	2,272
Redeemable warrants valuation adjustment	(1,968)	614	(1,732)	1,558
Net loss	(6,587)	(2,740)	(11,895)	(5,900)
Other Comprehensive Income (Loss):
Unrealized gain (loss) on marketable securities	306	(543)	890	(402)
Realized gain (loss) on marketable securities	(168)	14	(205)	509
Less: Premium amortization	24		132
Net comprehensive loss	$ (6,425)	$ (3,269)	$ (11,078)	$ (5,793)
Basic and diluted loss per share	$ (0.05)	$ (0.02)	$ (0.09)	$ (0.04)
Weighted average shares outstanding basic and diluted	137,012,240	135,496,311	136,260,727	135,379,622